Top Markets
#1 Nesa Nesa +813.42%
#2 Merlin's Seal BTC Merlin's Seal BTC +45.94%
#3 EXOD EXOD +22.78%
#4 TENDIES TENDIES +13.33%
#5 Venom Venom +11.00%
#6 Fartcoin Fartcoin +10.19%
#7 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +9.47%
#8 PondCoin PondCoin +9.15%
#9 Cash Cat Cash Cat +9.03%
#10 Pons Pons +8.78%
Coin of the day
Nesa Nesa
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
InflaRx N.V. InflaRx N.V.

InflaRx N.V.

IF0
Classifica tra le azioni #19672
InflaRx N.V. operates as a clinical-stage biopharmaceutical firm, specializing... InflaRx N.V. operates as a clinical-stage biopharmaceutical firm, specializing in the identification and advancement of C5a inhibitors. Their primary operational territories are Germany and the United States. C5a, an inflammatory mediator, plays a critical role in the advancement of various autoimmune and inflammatory conditions. The company's leading therapeutic candidate, vilobelimab, is an innovative, intravenously administered, first-in-class monoclonal antibody designed to target C5a. This compound has successfully completed Phase III clinical trials for treating hidradenitis suppurativa, a severe, chronic, and debilitating systemic inflammatory skin disease. Furthermore, vilobelimab is undergoing Phase II trials for anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disorder. An exploratory Phase IIa study is also underway for pyoderma gangraenosum, a persistent inflammatory skin condition. Additionally, vilobelimab is in Phase II clinical development for locally advanced or metastatic cutaneous squamous cell carcinoma that is resistant or refractory to PD-1/PD-L1 inhibitors. Beyond their lead candidate, InflaRx is developing INF904, an oral small molecule drug, intended for currently undisclosed chronic inflammatory and autoimmune diseases. Another pipeline asset, IFX002, is in preclinical stages, targeting chronic inflammation and autoimmune diseases. The company has established strategic alliances, including a co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. and a clinical trial collaboration and supply agreement with Merck & Co. Inc. Established in 2007, the company was initially known as Fireman B.V. before adopting the name InflaRx N.V. in 2017. Its corporate headquarters are located in Jena, Germany.
Prezzo delle azioni
$3.49
Ultima sincronizzazione: 2022-08-12
Capitalizzazione di mercato
$154.10M
Variazione (1 giorno)
12.28%
Variazione (1 anno)
0.00%
Paese
DE
Scambia InflaRx N.V. (IF0)

Categoria

Healthcare
Il prezzo IF0 con la capitalizzazione del mercato della B
InflaRx N.V. InflaRx N.V.
IF0
$3.49
Capitalizzazione di mercato di InflaRx N.V.(IF0)
Capitalizzazione di mercato: $154.10M
A partire dal August 2026, InflaRx N.V. ha una capitalizzazione di mercato pari a $154.10M. Questo rende InflaRx N.V. la 19672nd azienda più preziosa al mondo per capitalizzazione di mercato secondo i nostri dati. La capitalizzazione di mercato è il valore totale delle azioni in circolazione di una società quotata e viene comunemente utilizzata per misurarne il valore.
Storia della capitalizzazione di mercato di InflaRx N.V. dal 2019 al 2026
IF0 in paragone con la classifica dei più popolari stocks
Il prezzo per IF0 Attivo B Capitalizzazione del mercato a B Risultati
InflaRx N.V. InflaRx N.V.
$116,562 $154.10M
NVIDIA Corporation NVIDIA Corporation
NVDA
$5.152T +3,343,508.54%
InflaRx N.V. InflaRx N.V.
$102,639 $154.10M
Apple Inc. Apple Inc.
AAPL
$4.537T +2,944,113.34%
InflaRx N.V. InflaRx N.V.
$94,303.21 $154.10M
Alphabet Inc. Alphabet Inc.
GOOG
$4.169T +2,705,012.68%
InflaRx N.V. InflaRx N.V.
$82,398.88 $154.10M
Microsoft Corporation Microsoft Corporation
MSFT
$3.642T +2,363,534.01%
InflaRx N.V. InflaRx N.V.
$63,449.27 $154.10M
Amazon.com, Inc. Amazon.com, Inc.
AMZN
$2.805T +1,819,959.23%